肝癌患者活体供肝移植后肿瘤复发的相关因素
摘要
肝移植能够去除肝脏肿瘤,同时治愈肝硬化,具有传统的肿瘤切除术无法比拟的优势,所以肝移植被认为是肝癌合并肝硬化患者较理想的治疗方法。由于尸体供肝来源相对缺乏,现在,国际上各大肝移植中心已较多的选择活体供肝移植(LDLT)治疗肝癌。随着LDLT增多及术后随访时间的延长,肿瘤的复发和转移逐渐成为影响肝癌受者术后存活率的主要因素之一。肝癌的复发及转移是一个多步骤、多环节的过程,其分子机制涉及癌基因、抑癌基因、转移相关基因、生长因子及其受体、粘附分子、细胞外基质、肿瘤血管及机体免疫等多个环节。同样,活体移植肝的肝癌复发和转移也是一多环节、多阶段的过程,有其特殊的规律。
出处
《中华器官移植杂志》
CAS
CSCD
北大核心
2009年第8期510-511,共2页
Chinese Journal of Organ Transplantation
参考文献21
-
1Gondolesi GE,Roayaie S,Munoz L,et al.Adult living donor liver transplantation for patients with hepatocellular carcinoma:extending UNOS priority criteria.Ann Surg,2004,239(2):142-149.
-
2Todo S,Furukawa H; Japanese Study Group on Organ Transplantation.Living donor liver transplantation for adult patients with hepatocellular carcinoma:experience in Japan.Ann Surg,2004,240(3):451-159.
-
3Takada Y,Ueda M,Ito T,et al.Living donor liver transplantation as a second-line therapeutic strategy for patients with hepatocellular carcinoma.Liver Transpl,2006,12(6):912-919.
-
4Fisher RA,Kulik LM,Freise CE,et al.Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation.Am J Transplant,2007,(6):1601-1608.
-
5Roayaie S,Frischer JS,Emre SH,et al.Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters.Ann Surg,2002,235(4):533-539.
-
6Lee KW,Park JW,Joh JW,et al.Can we expand the Milan criteria for hepatocellular carcinoma in living donor liver transplantation? Transplant Proc,2004,36(8):2289-2290.
-
7Figueras J,Ibanez L,Ramos E,et al.Selection criteria for liver transplantation in early-stage hepatocellular carcinoma with cirrhosis:results of a multicenter study.Liver Transpl,2001,7(10):877-883.
-
8Ho MC,Wu YM,Hu RH,et al.Liver transplantation for patients with hepatocellular carcinoma.Transplant Proc,2004,36(8):2291-2292.
-
9Marubashi S,Dono K,Nagano H,et al.Detection of AFP mRNA-expressing cells in the peripheral blood for prediction of HCC recurrence after living donor liver transplantation.Transpl Int,2007,20(7):576-582.
-
10Vivarelli M,Cucchetti A,Piscaglia F,et al.Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma:key role of immunosuppression.Liver Transpl,2005,11(5):497-503.
二级参考文献12
-
1Mazzaferro V,Rondinara GF,Rossi G,et al.Milan multicenter experience in liver transplantation for hepatocellular carcinomal.Transplant Proc,1994,26:3557-3560.
-
2Yazawa H,Kato T,Nakada T,et al.Glucocorticoid hormone suppression of human neutrophil-mediated tumor cell cytostasis.Int J Cancer,1999,81:74-80.
-
3Ho WL,Wu CC,Yeh DC,et al.Roles of the glucocorticoid in resectable hepatocellular carcinoma.Surgery,2002,13:19-25.
-
4Punch JD,Shieck VL,Campbell DA,et al.Corticosteroid withdrawal after liver transplantation.Surgery,1995,118 :783-788.
-
5Everson G,Trouillot T,Wachs M,et al.Early steroid withdrawal in liver transplantation is safe and beneficial.Liver Transplant Surg,1999,5 :48.
-
6Pirenne J,Aerts R,Koshiba T,et al.Steroid-free immunosuppression during and after liver transplantation-a 3-yr followup report.Clin Transplant,2003,17 :177-182.
-
7Innocenti F,Hepp J,Humeres R,et al.Rapid steroid taper and Neroal monotherapy in liver transplantation in Chile:a step in the right direction? Transplant Proc,2005,37:2179-2180.
-
8Padbury R,Gunson B,Dousset B,et al.Steroid withdrawal from long term immunosuppression in liver allograft recipients.Transplantation,1993,55 :789.
-
9Jain A,Kashyap R,Marsh W,et al.Reasons for long-term use of steroid in primary adult liver transplantation under tacrolimus.Transplantation,2001,71:1102-1106.
-
10Stegall MD,Everson G,Schroter G,et al.Prednisone withdrawal late after adult liver transplantation reduces diabetes,hypertension and hypercholesterolemia without causing graft loss.Hepatology,1997,25:173.
共引文献7
-
1陈知水,何凡,曾凡军,明长生,蒋继贫,杜敦峰,刘斌.肝移植术后应用IL-2受体阻断剂早期撤离激素的临床研究[J].中华普通外科杂志,2007,22(4):246-249. 被引量:1
-
2高庆军,赵鑫,窦剑,曹经琳,任贵军,曾强,王洋,邸恩昌.肝移植治疗原发性肝癌的临床分析[J].临床荟萃,2007,22(13):971-972.
-
3兰辉,彭民浩.肝癌肝移植术后肿瘤复发相关因素研究进展[J].广西医学,2007,29(7):1042-1044. 被引量:3
-
4贾瑛,王帅.肝移植患者血糖的动态变化及危险因素探讨[J].天津医药,2007,35(9):670-672. 被引量:3
-
5胡安斌,何晓顺,吴志鹏,朱晓峰,马毅,王东平,王国栋,邰强,鞠卫强,巫林伟,黄洁夫.肝移植术后激素七天撤离方案的临床疗效评价[J].中华外科杂志,2008,46(15):1126-1128. 被引量:2
-
6王秀萍,王文花.肺癌临床诊断中肿瘤标志物CA153、CA125检验应用的价值[J].中国医药指南,2016,14(12):180-181. 被引量:4
-
7陈榕,江涛,张冬华,郝保兵,王轩.原发性肝癌患者肝移植术后无激素免疫抑制方案的临床疗效[J].中华肝胆外科杂志,2017,23(9):602-606. 被引量:6
-
1严律南.保证活体肝移植供、受者安全的几个问题[J].中华器官移植杂志,2010(4):197-198.
-
2王少发,何晓顺,李子平,彭振鹏,孙灿辉,张中伟,胡安斌,黄洁夫.肝中动脉的影像学解剖特点与活体供肝移植的相关性[J].中华器官移植杂志,2009,30(10):608-611. 被引量:5
-
3刘旭.MTA-1及PCNA在腺性膀胱炎中的表达及临床意义[J].中国实用医药,2015,10(3):71-72.
-
4黄小梅,黄丹,刘月英,胡卿香,胡丽芳.1例成人间活体供肝移植围术期供受体护理体会[J].当代护士(中旬刊),2012,19(10):159-161.
-
5陈实,彭承宏.小肝综合征的研究进展[J].中华器官移植杂志,2009,30(10):638-640. 被引量:3
-
6刘鹏.肝细胞癌的活体供肝移植治疗[J].中华器官移植杂志,2009,30(8):507-509.
-
7罗燕,周琛云,张梅,彭玉兰.活体供肝移植患者围手术期彩色多普勒超声检查的价值[J].中国医学影像技术,2005,21(10):1522-1524. 被引量:4
-
8张阳德,王光锁.活体部分肝移植临床进展[J].中国现代医学杂志,2002,12(12):39-43. 被引量:2
-
9侯二文,王禾,马建军,李瑞晓,唐启胜.MTA1在膀胱癌的表达及其与预后的相关性[J].现代泌尿外科杂志,2014,19(4):263-266. 被引量:5
-
10李鹏,赵向东,李厚祥,高田泰次.单段活体供肝移植16例报告——日本京都大学经验介绍[J].中华器官移植杂志,2006,27(4):245-246. 被引量:3